• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, October 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

Fighting deadly drug resistant bacteria in intestines with new antibiotic

Bioengineer by Bioengineer
January 18, 2019
in Immunology
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A new antibiotic is being heralded as a breakthrough in the war against a superbug

IMAGE

Credit: istock


A new antibiotic developed by a Flinders University researcher is being heralded as a breakthrough in the war against a drug resistant superbug.

Bacteria are winning the fight against antibiotics as they evolve to fight off traditional treatments, threatening decades of advancements in modern medicine, with predictions they will kill over 10 million people by 2050.

The scientific development of new, effective and safe antibiotics is crucial in addressing the ever-growing threat posed by drug resistant bacteria around the world.

Clostridium difficile infection (CDI) is a potentially deadly infection in the large intestine most common in people who need to take antibiotics for a long period of time, particularly in Australia’s ageing population.

Dr Ramiz Boulos, adjunct research associate at Flinders University and CEO of Boulos & Cooper Pharmaceuticsals, says the fact CDI is becoming resistant to traditional antibiotics is alarming and highlights the need to develop more effective treatments.

“Cases of CDI disease are rising and the strains are becoming more lethal. If there is an imbalance in your intestines it can begin to grow and release toxins that attack the lining of the intestines which leads to symptoms,” says Dr Boulos.

Over the past ten years, various strains of C. difficile have emerged, and are associated with outbreaks of severe infections worldwide. One particular strain is easily transmitted between people and has been responsible for large outbreaks in hospitals in the United States and Europe.

“It’s concerning when you consider CDI is one of the most common infections acquired during hospital visits in the Western hemisphere, and the most likely cause of diarrhoea for patients and staff in hospitals.”

But when doses of a new antibiotic called Ramizol were given to hamsters infected with a lethal dose of the bacteria, a significant proportion of hamsters survived the infection.

In a recent safety study in rats evaluating the effect of repeated exposure of the antibiotic, no rats experienced serious side effects or changes in weight.

“Our research indicates Ramizol is an extremely well-tolerated antibiotic in rats, with good microbiology and antioxidant properties. It also has high chemical stability and is scalable because of the low cost of manufacturing, which could make it a viable treatment option.”

Forty-eight rats were given a high dose of a new class of antibiotic for 14 days to assess its safety.

The research, which was undertaken jointly by Boulos & Cooper Pharmaceuticals, US- based Product Safety Labs and ToxStrategies and Flinders University was recently published in journal Scientific Reports.

“We are pleased with these results for two reasons. Firstly, we were able to give the rats a very high dose without mortalities or side effects,”

“Additionally, there were no changes in mean body weight, weight gain, food consumption or food efficiency for male and female rats attributable to Ramizol.”

“We believe Ramizol has the potential to be the standard of care for treating CDI and has the potential to be a blockbuster drug.”

###

The researchers say these findings open up a potentially simple treatment but further studies are required to pursue its development.

The study ‘A 14-day repeat dose oral gavage range-finding study of a first-in-class CDI investigational antibiotic, in rats” is freely available at https://www.nature.com/articles/s41598-018-36690-9

Media Contact
Dr Ramiz Boulos
[email protected]
61-431-150-538

Related Journal Article

http://dx.doi.org/10.1038/s41598-018-36690-9

Tags: AgingBiologyBiotechnologyDisease in the Developing WorldInfectious/Emerging DiseasesMedicine/HealthMicrobiologyNanotechnology/MicromachinesPharmaceutical SciencePublic Health
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

UMass Amherst grad student awarded fellowship for food allergy research

July 23, 2021
IMAGE

Less-sensitive COVID-19 tests may still achieve optimal results if enough people tested

July 22, 2021

Public trust in CDC, FDA, and Fauci holds steady, survey shows

July 20, 2021

USC study shows male-female differences in immune cell function

July 19, 2021
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    94 shares
    Share 38 Tweet 24
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    92 shares
    Share 37 Tweet 23
  • Physicists Develop Visible Time Crystal for the First Time

    75 shares
    Share 30 Tweet 19
  • New Insights Suggest ALS May Be an Autoimmune Disease

    71 shares
    Share 28 Tweet 18

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Empowering Older Adults: Shared Decision-Making in Nursing

Whole Genome Analysis Uncovers Variations in Goat Pigmentation

Boosting Malonylation Site Detection with AlphaFold2

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 62 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.